Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial
Background: Probiotics are commonly used after bariatric surgery; however, uncertainty remains regarding their efficacy. Our aim was to compare the effect of probiotics vs placebo on hepatic, inflammatory and clinical outcomes following laparoscopic sleeve gastrectomy (LSG). Methods: This randomized...
Gespeichert in:
Veröffentlicht in: | International Journal of Obesity 2018-02, Vol.42 (2), p.147-155 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background:
Probiotics are commonly used after bariatric surgery; however, uncertainty remains regarding their efficacy. Our aim was to compare the effect of probiotics vs placebo on hepatic, inflammatory and clinical outcomes following laparoscopic sleeve gastrectomy (LSG).
Methods:
This randomized, double-blind, placebo-controlled, trial of 6-month treatment with probiotics (Bio-25; Supherb) vs placebo and 6 months of additional follow-up was conducted among 100 morbidly obese nonalcoholic fatty liver disease (NAFLD) patients who underwent LSG surgery. The primary outcome was a reduction in liver fat content, measured by abdominal ultrasound, and secondary outcomes were improvement of fibrosis, measured by shear-wave elastography, metabolic and inflammatory parameters, anthropometrics and quality of life (QOL). Fecal samples were collected and analyzed for microbial composition.
Results:
One hundred patients (60% women, mean age of 41.9±9.8 years and body mass index of 42.3±4.7 kg m
−2
) were randomized, 80% attended the 6-month visit and 77% completed the 12-month follow-up. Fat content and NAFLD remission rate were similarly reduced in the probiotics and placebo groups at 6 months postsurgery (−0.9±0.5 vs −0.7±0.4 score;
P
=0.059 and 52.5 vs 40%;
P
=0.262, respectively) and at 12 months postsurgery. Fibrosis, liver-enzymes, C-reactive protein (CRP), leptin and cytokeratin-18 levels were significantly reduced and QOL significantly improved within groups (
P
⩽0.014 for all), but not between groups (
P
⩾0.173 for all) at 6 and 12 months postsurgery. Within-sample microbiota diversity (alpha-diversity) increased at 6-month postsurgery compared with baseline in both study arms (
P
⩽0.008) and decreased again at 12 months postsurgery compared with 6 months postsurgery (
P
⩽0.004) but did not reach baseline values.
Conclusions:
Probiotics administration does not improve hepatic, inflammatory and clinical outcomes 6- and 12 months post-LSG. |
---|---|
ISSN: | 0307-0565 1476-5497 |
DOI: | 10.1038/ijo.2017.210 |